Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
The cereblon E3 ligase modulator cemsidomide showed activity against multiple myeloma and two types of non–Hodgkin lymphoma in a phase I study.
This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...
Major Finding: Pharmacologic inhibition of EZH2 sensitizes preclinical models of B cell lymphoma to T-cell immunotherapy. Concept: EZH2 inhibition enhances T-cell recruitment, T-cell–B-cell ...
Copyright held by the owner/author(s).
The ALK tyrosine kinase inhibitor (TKI) ensartinib (Ensacove; Xcovery) was approved for patients with locally advanced or metastatic ALK-positive non–small cell lung cancer (NSCLC). The decision was ...
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license ...
Major Finding: In breast cancer, chemotherapy elicits stronger antitumor responses when administered during estrus. Concept: The estrous cycle alters macrophage infiltration, epithelial-mesenchymal ...
1Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. *Corresponding Author: Maryam Sarraf Yazdy, U.S. Food and Drug Administration, WO22 Room 2169, ...
Major Finding: Aging impedes lung tumorigenesis by limiting the stemness of the alveolar type 2 cell of origin. Concept: The effect of age on tumorigenesis is mediated by a disruption of iron ...
Machine learning could better stratify patients with metastatic ER-positive, HER2-negative breast cancer who are more or less likely to benefit from CDK4/6 inhibition up front. At Memorial Sloan ...